Accendra Health Finalizes $300M Revolver, Prices New First- and Second-Lien Notes
Summary
Accendra Health has finalized a significant overhaul of its capital structure, pricing new first- and second-lien notes due 2032 and 2033, and securing a new $300 million revolving credit facility due 2030. This follows the comprehensive balance sheet optimization and debt exchange offers detailed in multiple SEC filings and news since May, including the successful early results announced in an 8-K earlier today. The new financing provides critical liquidity and extends debt maturities, which is essential for the company given its reported losses and declining revenue.
At the time of this announcement, ACH was trading at $3.03 on NYSE in the Life Sciences sector, with a market capitalization of approximately $232M. The 52-week trading range was $1.84 to $9.55. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: Wiseek News.